Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Equity Valuations Lofty, Earnings Lousy: Morganlander
22:11 - Stifel Nicolaus' Chad Morganlander and Bloomberg's Michael Regan discuss the global selloff in stocks with Bloomberg's Pimm Fox on "Taking Stock." (Source: Bloomberg)
  • `Time Is of the Essence' for Greece to Reach Deal: Lew
  • A Penthouse Perspective on NYC Real Estate
  • Will the Comcast-Time Warner Cable Merger Ever Happen?